MIF-1 / Pro-Leu-Gly-NH₂: preparation and storage
Intended for research use only. Not a medicinal product.
Contents (8 sections)
Identity and material form
MIF-1, melanostatin, is the tripeptide Pro-Leu-Gly-NH₂. Its C-terminal amide is part of its identity: free-acid Pro-Leu-Gly is a different molecule. Tyr-MIF-1 contains an additional tyrosine and is also distinct. MIF is also an abbreviation for macrophage migration inhibitory factor, a much larger protein. Its buffers and protein assays should not be transferred to this tripeptide.
Check sequence, amidation, salt form and quantitative content. Short length does not make the powder composition self-evident: water and counterions may contribute to its mass. Concentrations here use mass units rather than assigning precise molarity to an unspecified form.
What the research context means
Barbeau examined Pro-Leu-Gly-NH₂ together with levodopa in people in a 1975 paper [1]. This supplies historical pharmacological context, not current preparation instructions for a research vial. It establishes neither post-dissolution shelf life, suitability of bacteriostatic water nor a standard concentration for a receptor assay.
In a laboratory dopamine-system experiment, separately document agonist, receptor model and functional endpoint. Assess compound interactions with controls for each compound alone and for their vehicles. A change in combination response is not a standalone measurement of residual MIF-1 concentration.
Solvent and final matrix
Do not dissolve the amidated tripeptide using a protocol for the large MIF protein. Start with the actual salt specification and a small-sample check. Hydrophobic leucine alone does not establish a need for DMSO, and a short sequence alone does not guarantee any chosen aqueous concentration.
Check both the initial solution and its dilution into final buffer. If a receptor assay uses a membrane fraction, its proteins and lipids create a different environment from clean water. Comparing quantitative recovery before and after matrix contact helps distinguish lost available reagent from a changed biological response.
Laboratory calculation example
A hypothetical 2.00 mg of material in a final 4.00 mL gives 0.500 mg/mL. To obtain 25.0 µg/mL in a final 1.00 mL, transfer 50.0 µL and bring to 1.00 mL. For 2.50 µg/mL, first prepare a 50.0 µg/mL intermediate through a 1:10 dilution, then again transfer 50.0 µL within a final 1.00 mL.
This illustrates manageable transfer volumes rather than selecting a dopamine-receptor exposure concentration. State whether mass refers to peptide, salt or total cake. Label each intermediate separately to avoid confusing MIF-1 with Tyr-MIF-1.
Quality checks during handling
MIF-1 contains no Tyr or Trp, whereas Tyr-MIF-1 contains tyrosine. The same A280 approach therefore does not give comparable concentrations for the two reagents. MIF-1 needs a suitable calibrated assay. Identity checks must distinguish the amide from free acid rather than merely confirming three amino-acid residues.
If response changes after storage, first compare quantitative content and impurity profile against a fresh sample. Do not compensate for unknown losses by increasing stock volume: that also changes vehicle exposure. For prolonged experiment series, retain a control aliquot with minimal thawing history.
When comparing MIF-1 and Tyr-MIF-1, do not use one nonspecific protein calibrator without assessing each compound's response. Adding tyrosine changes the analytical signal as well as the name. For a receptor-effect comparison, establish reagent quantity and chemical integrity separately from the functional assay.
Prepare a sample that undergoes all membrane and tube contact steps without response measurement. Analysing it helps check quantitative recovery. That control has its own matrix: a method validated in water may not suit a membrane suspension.
If old stock produces a different result, check MIF-1, the second active compound and receptor-system condition separately. A combined endpoint cannot automatically assign the difference to MIF-1 alone.
Dry material and solution need separate conditions
For long-term storage of a dry synthetic peptide, use a freezer, commonly −20 °C or below, where the specification supports it. Allow the sealed vial to reach room temperature before opening so moisture does not condense on cold powder. A refrigerator at +2–8 °C can be a working option for dry material needed within a week or a month only when the supplier supports that interval. Planning to use a vial soon does not establish its shelf life.
A solution needs its own record: solvent, concentration, pH, preparation date, temperature and permitted holding time. Do not transfer the dry-material expiry to the solution. Where freezing is supported, prepare aliquots for individual experiments; thawing the remainder again needs separate validation. Bacteriostatic water contains a preservative that can change a cell-assay result and is not a default solvent for every peptide.
Practical questions
Is MIF-1 recombinant MIF? No; the names only partly overlap. Can free acid replace the amide? That changes identity and requires a separate experiment. Does an old clinical paper establish suitability of a current laboratory vial for human use? No: reagent specification and the studied formulation are separate matters.
Does this page establish a month of refrigerated solution storage? No. That interval requires data for the actual solvent, concentration and temperature.
Monograph · Product page · Certificates of analysis
General reagent preparation · Bacteriostatic water compatibility · Storage and expiry
End of article
MIF-1 (Pro-Leu-Gly-NH₂)
for laboratory research
Packs and current prices on the product page.